Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes

References

• Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005; 25:6 - 17
   PubMed Web of Science ®Google Scholar
• Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9:862 - 873
   PubMed Web of Science ®Google Scholar
• Saitoh S, Cunningham J, De Vries EM, McGovern RM, Schroeder JJ, Hartmann A, et al. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 1994; 9:2869 - 2875
   PubMed Web of Science ®Google Scholar
• Hernandez-Vargas H, Ballestar E, Carmona-Saez P, von Kobbe C, Banon-Rodriguez I, Esteller M, et al. Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis and identification of novel targets of p53. Int J Cancer 2006; 119:1164 - 1175
   PubMed Web of Science ®Google Scholar
• Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 2005; 331:868 - 880
   PubMed Web of Science ®Google Scholar
• Troester MA, Hoadley KA, Sorlie T, Herbert BS, Borresen-Dale AL, Lonning PE, et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004; 64:4218 - 4226
   PubMed Web of Science ®Google Scholar
• Eisold S, Linnebacher M, Ryschich E, Antolovic D, Hinz U, Klar E, et al. The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol 2004; 10:3583 - 3589
   PubMed Web of Science ®Google Scholar
• Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263 - 269
   PubMed Web of Science ®Google Scholar
• Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807 - 810
   PubMed Web of Science ®Google Scholar
• Botchkarev VA, Komarova EA, Siebenhaar F, Botchkareva NV, Komarov PG, Maurer M, et al. p53 is essential for chemotherapy-induced hair loss. Cancer Res 2000; 60:5002 - 5006
   PubMed Web of Science ®Google Scholar
• Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature 1992; 358:83 - 86
   PubMed Web of Science ®Google Scholar
• Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 1992; 6:1143 - 1152
   PubMed Web of Science ®Google Scholar
• Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252:1708 - 1711
   PubMed Web of Science ®Google Scholar
• Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370:220 - 223
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005; 309:1732 - 1735
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303:1010 - 1014
   PubMed Web of Science ®Google Scholar
• Erster S, Moll UM. Stress-induced p53 runs a direct mitochondrial death program: Its role in physiologic and pathophysiologic stress responses in vivo. Cell Cycle 2004; 3:1492 - 1495
   PubMed Web of Science ®Google Scholar
• Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004; 24:6728 - 6741
   PubMed Web of Science ®Google Scholar
• Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11:577 - 590
   PubMed Web of Science ®Google Scholar
• Somasundaram K, El-Deiry WS. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 1997; 14:1047 - 1057
   PubMed Web of Science ®Google Scholar
• Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003; 100:1931 - 1936
   PubMed Web of Science ®Google Scholar
• Iwakuma T, Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 2007; 26:2177 - 2184
   PubMed Web of Science ®Google Scholar
• Chao C, Saito S, Kang J, Anderson CW, Appella E, Xu Y. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J 2000; 19:4967 - 4975
   PubMed Web of Science ®Google Scholar
• Jimenez GS, Nister M, Stommel JM, Beeche M, Barcarse EA, Zhang XQ, et al. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat Genet 2000; 26:37 - 43
   PubMed Web of Science ®Google Scholar
• Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996; 16:4952 - 4960
   PubMed Web of Science ®Google Scholar
• el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817 - 825
   PubMed Web of Science ®Google Scholar
• Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1:3 - 11
   PubMed Web of Science ®Google Scholar
• Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7:683 - 694
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7:673 - 682
   PubMed Web of Science ®Google Scholar
• Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288:1053 - 1058
   PubMed Web of Science ®Google Scholar
• Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188:2033 - 2045
   PubMed Web of Science ®Google Scholar
• Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19:1735 - 1743
   PubMed Web of Science ®Google Scholar
• Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000; 14:981 - 993
   PubMed Web of Science ®Google Scholar
• Mattia M, Gottifredi V, McKinney K, Prives C. p53-Dependent p21 mRNA elongation is impaired when DNA replication is stalled. Mol Cell Biol 2007; 27:1309 - 1320
   PubMed Web of Science ®Google Scholar
• Tanaka T, Ohkubo S, Tatsuno I, Prives C. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 2007; 130:638 - 650
   PubMed Web of Science ®Google Scholar
• Ohkubo S, Tanaka T, Taya Y, Kitazato K, Prives C. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J Biol Chem 2006; 281:16943 - 16950
   PubMed Web of Science ®Google Scholar
• Gottifredi V, Shieh S, Taya Y, Prives C. p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc Natl Acad Sci USA 2001; 98:1036 - 1041
   PubMed Web of Science ®Google Scholar
• Gottifredi V, Shieh SY, Prives C. Regulation of p53 after different forms of stress and at different cell cycle stages. Cold Spring Harb Symp Quant Biol 2000; 65:483 - 488
   PubMedGoogle Scholar
• Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996; 16:4961 - 4971
   PubMed Web of Science ®Google Scholar
• Donner AJ, Szostek S, Hoover JM, Espinosa JM. CDK8 Is a Stimulus-Specific Positive Coregulator of p53 Target Genes. Mol Cell 2007; 27:121 - 133
   PubMed Web of Science ®Google Scholar
• Donner AJ, Hoover JM, Szostek SA, Espinosa JM. Stimulus-specific transcriptional regulation within the p53 network. Cell Cycle 2007; 6:2594 - 2598
   PubMed Web of Science ®Google Scholar
• Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev 2006; 20:601 - 612
   PubMed Web of Science ®Google Scholar
• Espinosa JM, Verdun RE, Emerson BM. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 2003; 12:1015 - 1027
   PubMed Web of Science ®Google Scholar
• Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002; 62:7316 - 7327
   PubMed Web of Science ®Google Scholar
• Bouvard V, Zaitchouk T, Vacher M, Duthu A, Canivet M, Choisy-Rossi C, et al. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. Oncogene 2000; 19:649 - 660
   PubMed Web of Science ®Google Scholar
• Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102:849 - 862
   PubMed Web of Science ®Google Scholar
• Kurihara A, Nagoshi H, Yabuki M, Okuyama R, Obinata M, Ikawa S. Ser46 phosphorylation of p53 is not always sufficient to induce apoptosis: multiple mechanisms of regulation of p53-dependent apoptosis. Genes Cells 2007; 12:853 - 861
   PubMed Web of Science ®Google Scholar
• Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004; 279:53015 - 53022
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844 - 848
   PubMed Web of Science ®Google Scholar
• Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8:781 - 794
   PubMed Web of Science ®Google Scholar
• Das S, Raj L, Zhao B, Kimura Y, Bernstein A, Aaronson SA, et al. Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell 2007; 130:624 - 637
   PubMed Web of Science ®Google Scholar
• Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 2002; 99:95 - 100
   PubMed Web of Science ®Google Scholar
• Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124:207 - 219
   PubMed Web of Science ®Google Scholar
• Morachis JM, Murawsky CM, Emerson BM. Regulation of the p53 transcriptional response by structurally diverse core promoters. Genes Dev 2010; 24:135 - 147
   PubMed Web of Science ®Google Scholar
• Gomes NP, Espinosa JM. Gene-specific repression of the p53 target gene PUMA via intragenic CTCF-Cohesin binding. Genes Dev 2010; 24:1022 - 1034
   PubMed Web of Science ®Google Scholar
• Yee KS, Vousden KH. Contribution of membrane localization to the apoptotic activity of PUMA. Apoptosis 2008; 13:87 - 95
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xing D, Liu L. PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-XL during UV-induced apoptosis. Mol Biol Cell 2009; 20:3077 - 3087
   PubMed Web of Science ®Google Scholar
• Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007; 130:77 - 88
   PubMed Web of Science ®Google Scholar
• Agalioti T, Chen G, Thanos D. Deciphering the transcriptional histone acetylation code for a human gene. Cell 2002; 111:381 - 392
   PubMed Web of Science ®Google Scholar
• Stewart MD, Li J, Wong J. Relationship between histone H3 lysine 9 methylation, transcription repression and heterochromatin protein 1 recruitment. Mol Cell Biol 2005; 25:2525 - 2538
   PubMed Web of Science ®Google Scholar
• Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20:1123 - 1136
   PubMed Web of Science ®Google Scholar
• Boyle AP, Davis S, Shulha HP, Meltzer P, Margulies EH, Weng Z, et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 2008; 132:311 - 322
   PubMed Web of Science ®Google Scholar
• Cuddapah S, Jothi R, Schones DE, Roh TY, Cui K, Zhao K. Global analysis of the insulator binding protein CTCF in chromatin barrier regions reveals demarcation of active and repressive domains. Genome Res 2009; 19:24 - 32
   PubMed Web of Science ®Google Scholar
• Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD, et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 2007; 128:1231 - 1245
   PubMed Web of Science ®Google Scholar
• West AG, Huang S, Gaszner M, Litt MD, Felsenfeld G. Recruitment of histone modifications by USF proteins at a vertebrate barrier element. Mol Cell 2004; 16:453 - 463
   PubMed Web of Science ®Google Scholar
• Rada-Iglesias A, Ameur A, Kapranov P, Enroth S, Komorowski J, Gingeras TR, et al. Whole-genome maps of USF1 and USF2 binding and histone H3 acetylation reveal new aspects of promoter structure and candidate genes for common human disorders. Genome Res 2008; 18:380 - 392
   PubMed Web of Science ®Google Scholar
• Cheng J, Kapranov P, Drenkow J, Dike S, Brubaker S, Patel S, et al. Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution. Science 2005; 308:1149 - 1154
   PubMed Web of Science ®Google Scholar
• Phillips JE, Corces VG. CTCF: master weaver of the genome. Cell 2009; 137:1194 - 1211
   PubMed Web of Science ®Google Scholar
• Hou C, Dale R, Dean A. Cell type specificity of chromatin organization mediated by CTCF and cohesin. Proc Natl Acad Sci USA 2010; 107:3651 - 3656
   PubMed Web of Science ®Google Scholar
• Juven-Gershon T, Hsu JY, Theisen JW, Kadonaga JT. The RNA polymerase II core promoter—the gateway to transcription. Curr Opin Cell Biol 2008; 20:253 - 259
   PubMed Web of Science ®Google Scholar
• Butler JE, Kadonaga JT. Enhancer-promoter specificity mediated by DPE or TATA core promoter motifs. Genes Dev 2001; 15:2515 - 2519
   PubMed Web of Science ®Google Scholar
• Gomes NP, Espinosa JM. Differential regulation of p53 target genes: it's (core promoter) elementary. Genes Dev 2010; 24:111 - 114
   PubMed Web of Science ®Google Scholar
• Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103:1888 - 1893
   PubMed Web of Science ®Google Scholar
• Paris R, Henry RE, Stephens SJ, McBryde M, Espinosa JM. Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation. Cell Cycle 2008; 7:2427 - 2433
   PubMed Web of Science ®Google Scholar
• Komarnitsky P, Cho EJ, Buratowski S. Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. Genes Dev 2000; 14:2452 - 2460
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97:10014 - 10019
   PubMed Web of Science ®Google Scholar
• Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101:1241 - 1246
   PubMed Web of Science ®Google Scholar
• Yeo M, Lin PS, Dahmus ME, Gill GN. A novel RNA polymerase II C-terminal domain phosphatase that preferentially dephosphorylates serine 5. J Biol Chem 2003; 278:26078 - 26085
   PubMed Web of Science ®Google Scholar
• Mandal SS, Cho H, Kim S, Cabane K, Reinberg D. FCP1, a phosphatase specific for the heptapeptide repeat of the largest subunit of RNA polymerase II, stimulates transcription elongation. Mol Cell Biol 2002; 22:7543 - 7552
   PubMed Web of Science ®Google Scholar
• Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129:823 - 837
   PubMed Web of Science ®Google Scholar